Theralase® Researchers Invited to Present at International Conference in Germany Toronto, Ontario – September 4, 2018 Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers announced today that Theralase® researchers have been invited to present their latest research at the international conference, “Photodynamic Therapy and Photodiagnostics Update” to be held in Kochel am See (near Munich, Germany) on September  18 to 22, 2018. The “Photodynamic Therapy and Photodiagnostics Update” conference is a highly regarded event in the field of Photo Dynamic Therapy (“PDT”) bringing together researchers and clinicians working in all fields of PDT and Photo Diagnosis (“PD”) to foster scientific development of this technology in the fields of biology and medicine. Arkady Mandel, MD, PhD, DSc., Interim … Read More

Not for distribution to U.S. news wire services or dissemination in the United States. Toronto, Ontario – August 28, 2018 Theralase Technologies Inc. (the “Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations to safely and effectively destroy various cancers, is pleased to announce that it proposes to conduct a non-brokered private placement offering of up to 28,571,429 units at a price of $0.35 per unit for gross proceeds of up to $10 million.  Each unit will consist of one common share of the Company and one common share purchase warrant with each warrant entitling the holder to purchase one common share at an exercise price of $0.50 per share for a period of 24 months. The Company intends to use the proceeds of the offering for the following: – … Read More

Theralase® Provides Update on Upcoming Initiatives for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study Toronto, Ontario – August 27, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided a corporate update on the Phase II for the Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study. Photo Dynamic Therapy (“PDT”) utilizing the Company’s lead drug, TLD-1433, has met all expectations of the Company in the successfully completed Phase Ib NMIBC Clinical Study. In the Phase Ib study all 6 patients enrolled and treated (3 at the Maximum Recommended Starting Dose (“MRSD”) (0.35 mg/cm2) and 3 at the Therapeutic Dose (0.70 mg/cm2)) achieved both the primary (safety and tolerability as measured by Adverse Events (“AE”)) and … Read More

Toronto, Ontario – August 20, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has submitted a Clinical Trial Application (“CTA”) and Investigational Testing Authorization (“ITA”) for its TLD-1433 anti-cancer technology to Health Canada for review and approval. Pending Health Canada and the individual Canadian oncology location(s) Research Ethics Board’s (“REB”) approvals, and subject to securing the requisite financing, Theralase plans to commence a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study, entitled, “Photo Dynamic Therapy Using Laser Light Activated TLD-1433 in BCG-Unresponsive Patient Population” (“Study”) with select Canadian oncology locations. Theralase’s anti-cancer technology utilizes the proprietary Theralase TLC-3200 Medical Laser System to light activate the Company’s lead, patented PDC, TLD-1433, intended to treat NMIBC. … Read More

Patient Five and Six Demonstrate No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Company Successfully Completes 180 days Follow Up of the Phase Ib Study and Plans Regulatory Filings to Commence a Phase II Clinical Study that May Lead to Commercialization of the TLD-1433 Anti-Cancer Technology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) Toronto, Ontario – August 13, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient six, enrolled and treated in the recently completed Phase Ib NMIBC clinical study (“Study”). The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, with a secondary endpoint of pharmacokinetics (movement and exit of … Read More

Toronto, Ontario – July 26, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer released its 2Q2018 financial statements.Total revenue for the six-month period ended June 30, 2018 decreased to $910,690 from $1,016,734 for the same period in 2017, a 10% decrease. In Canada, revenue decreased 22% to $602,277 from $769,840. In the US, revenue decreased 13% to $183,460 from $211,453 and international revenue increased 252% to $124,953 from $35,441. The increase in international revenue in 2018 and the corresponding decrease in Canadian and US revenue is attributable to the Company hiring an International Sales Manager and restructuring the Canadian and US sales and marketing departments. Cost of sales for the six-month period ended June 30, 2018 … Read More

Patient Five Demonstrates No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Toronto, Ontario – July 16, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”). The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy. The exploratory outcome endpoint is defined as Recurrence-Free Survival (“RFS”), which is the interval from the day of the treatment to documented recurrence or death from any cause, … Read More

Toronto, Ontario – June 29, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy cancer is pleased to announce the release of three videos presented at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 22, 2018. The videos are as follows: Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study https://youtu.be/a_tacy_kND8 Michael Jewett MD, Professor of Surgery (Urology) at the University of Toronto discusses the proposed design of the Phase II NMIBC clinical study https://youtu.be/ytXPx0Ltb_Q Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase discusses the potential opportunities … Read More

Toronto, Ontario – June 22, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy various cancers is pleased to announce that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for the U.S. Patent Application No. 15/291,025: “Metal-Glycoprotein Complexes And Photodynamic Therapy Of Immune Privileged Sites With Same” that encompasses the Company’s Rutherrin® Based Photo Dynamic Therapy (“PDT”) for the treatment of cancers localised in immune privileged sites, such as: the eyes, brain and testis.   Inflammation, particularly at an immune-privileged site, induced by surgery, radiation or another anti-cancer modality may act as a “double edged sword”. On the positive side, an increase in inflammation may help trigger the activation of the body’s … Read More

Toronto, Ontario – June 11, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, intended to safely and effectively destroy cancer, has announced significant benefits of its Rutherrin® (TLD-1433 + transferrin) formulation in comparison to a clinically approved PDC Amino Levulinic Acid (“ALA”), in the destruction of Rat Glioma (“RG2”) brain tumours, representative of GlioBlastoma Multiforme (“GBM”), a deadly form of human brain cancer. As previously disclosed, Theralase demonstrated that rats subjected to RG2 cancer cells, developed brain tumours representative of GBM. After intravenous (“IV”) injection of Rutherrin® and subsequent laser light activation, these animals survived significantly longer that animals who did not receive treatment and/or were treated with ALA-PDT. Further research conducted by Theralase researchers has demonstrated that Rutherrin® is able to provide a significant (up to 400 %) improvement in survival in animals treated with … Read More